Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes

被引:99
作者
Cherney, David Z. I. [1 ]
Perkins, Bruce A. [2 ]
Soleymanlou, Nima [3 ]
Xiao, Fengxia [4 ]
Zimpelmann, Joseph [4 ]
Woerle, Hans-Juergen [5 ]
Johansen, Odd E. [6 ]
Broedl, Uli C. [5 ]
von Eynatten, Maximilian [7 ]
Burns, Kevin D. [4 ]
机构
[1] Univ Toronto, Toronto Gen Hosp, Dept Med, Div Nephrol, Toronto, ON M5G 2N2, Canada
[2] Univ Toronto, Toronto Gen Hosp, Dept Med, Div Endocrinol, Toronto, ON M5G 2N2, Canada
[3] Boehringer Ingelheim Canada Ltd Ltee, Burlington, ON, Canada
[4] Univ Ottawa, Dept Med, Ottawa Hosp Res Inst, Div Nephrol,Kidney Res Ctr, Ottawa, ON, Canada
[5] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[6] Boehringer Ingelheim Norway KS, Asker, Norway
[7] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA
基金
加拿大健康研究院;
关键词
D O I
10.1038/ki.2014.246
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:1057 / 1058
页数:2
相关论文
共 4 条
[1]   Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus [J].
Cherney, David Z. I. ;
Perkins, Bruce A. ;
Soleymanlou, Nima ;
Maione, Maria ;
Lai, Vesta ;
Lee, Alana ;
Fagan, Nora M. ;
Woerle, Hans J. ;
Johansen, Odd Erik ;
Broedl, Uli C. ;
von Eynatten, Maximilian .
CIRCULATION, 2014, 129 (05) :587-597
[2]   Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering? [J].
Gilbert, Richard E. .
KIDNEY INTERNATIONAL, 2014, 86 (04) :693-700
[3]  
Musetti C, 2014, KIDNEY INT, V85, P1243, DOI 10.1038/ki.2014.42
[4]   Increased Urinary Angiotensin-Converting Enzyme 2 in Renal Transplant Patients with Diabetes [J].
Xiao, Fengxia ;
Hiremath, Swapnil ;
Knoll, Greg ;
Zimpelmann, Joseph ;
Srivaratharajah, Kajenny ;
Jadhav, Deepak ;
Fergusson, Dean ;
Kennedy, Chris R. J. ;
Burns, Kevin D. .
PLOS ONE, 2012, 7 (05)